Introductory Note: This joint statement on Schedule 13G (this “Statement”) is filed on behalf of the Reporting Persons, in respect of shares of Common Stock, par value $0.0001 per share (“Common Stock”), of RayzeBio, Inc. (the “Issuer”).
Item 1(a). | Name of Issuer: |
RayzeBio, Inc.
Item 1(b). | Address of Issuer’s Principal Executive Offices: |
5505 Morehouse Drive, Suite 300
San Diego, CA 92121
Item 2(a). | Name of Person Filing: |
This Statement is being filed by Versant Venture Capital VII, L.P. (“Versant VII”), Versant Ventures VII GP, L.P. (“VV VII GP”), Versant Ventures VII GP-GP, LLC (“VV VII GP-GP”), Versant Vantage I, L.P. (“Vantage I”), Versant Vantage I GP, L.P. (“Vantage I GP”), Versant Vantage I GP-GP, LLC (“Vantage I GP-GP,” and together with Versant VII, VV VII GP, VV VII GP-GP, Vantage I, and Vantage I GP, the “Reporting Persons”).
Item 2(b) | Address of Principal Business Office, or if None, Residence: |
The address of the principal business office of each Reporting Person is c/o Versant Ventures, One Sansome Street, Suite 1650, San Francisco, CA 94104
Each of VV VII GP-GP and Vantage I GP-GP is a limited liability company organized under the laws of the State of Delaware. Each of Versant VII, VV VII GP, Vantage I and Vantage I GP is a limited partnership organized under the laws of the State of Delaware.
Item 2(d). | Title of Class of Securities: |
Common Stock, $0.0001 par value per share.
75525N107
Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a: |
Not applicable.
| (a) | Amount beneficially owned: |
See Row 9 of the cover page for each Reporting Person.*
See Row 11 of the cover page for each Reporting Person and the corresponding footnotes.*